Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Profit After Tax: 2018-2024

Historic Profit After Tax for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to -$45.3 million.

  • Silence Therapeutics' Profit After Tax rose 41.04% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.5 million, marking a year-over-year increase of 18.95%. This contributed to the annual value of -$45.3 million for FY2024, which is 16.45% up from last year.
  • According to the latest figures from FY2024, Silence Therapeutics' Profit After Tax is -$45.3 million, which was up 16.45% from -$54.2 million recorded in FY2023.
  • Over the past 5 years, Silence Therapeutics' Profit After Tax peaked at -$41.8 million during FY2020, and registered a low of -$54.2 million during FY2023.
  • Its 3-year average for Profit After Tax is -$50.0 million, with a median of -$50.3 million in 2022.
  • In the last 5 years, Silence Therapeutics' Profit After Tax plummeted by 67.16% in 2020 and then increased by 16.45% in 2024.
  • Silence Therapeutics' Profit After Tax (MRY) stood at -$41.8 million in 2020, then dropped by 29.74% to -$54.2 million in 2021, then rose by 7.17% to -$50.3 million in 2022, then fell by 7.74% to -$54.2 million in 2023, then increased by 16.45% to -$45.3 million in 2024.
  • Its last three reported values are -$45.3 million in FY2024, -$54.2 million for FY2023, and -$50.3 million during FY2022.